PMID- 34588833
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220427
IS  - 1179-271X (Print)
IS  - 1179-271X (Electronic)
IS  - 1179-271X (Linking)
VI  - 12
DP  - 2021
TI  - Minimal Clinically Important Differences (MCID) for the Western Ontario 
      Osteoarthritis of the Shoulder Index (WOOS) and the Oxford Shoulder Score (OSS).
PG  - 299-306
LID - 10.2147/PROM.S316920 [doi]
AB  - BACKGROUND: The minimal clinically important difference (MCID) is an important 
      instrument in the interpretation of changes in patient-reported outcome measures 
      (PROM). To our knowledge, no MCID of the Western Ontario Osteoarthritis of the 
      Shoulder Index (WOOS) score has ever been reported and no studies have reported 
      an MCID for the Oxford Shoulder Score (OSS) based on patients with glenohumeral 
      osteoarthritis, treated with an anatomical total shoulder arthroplasty (aTSA). 
      The aim of this study was to determine MCID for WOOS and OSS in a cohort of 
      patients with glenohumeral osteoarthritis treated with an aTSA. METHODS: All 
      patients treated with an aTSA for glenohumeral osteoarthritis at our institution 
      between March 2017 and February 2019 were included. Each patient completed the 
      WOOS and the OSS preoperatively and one year postoperatively. At one year, the 
      patients were asked to rate their overall improvement on a 7-point scale. We used 
      an anchor-based method as our primary method to calculate the MCID, supported by 
      two different distribution-based methods. RESULTS: A total of 45 primary aTSA 
      were included. The MCID of WOOS was 12.3 according to the anchor-based method and 
      14.2 and 10.3 according to the two distribution-based methods. The MCID of OSS 
      was 4.3 according to the anchor-based method and 5.8 and 4.3 according to the two 
      distribution-based methods. CONCLUSION: The anchor-based method is considered 
      superior to the distribution-based method, and therefore we advocate to use this 
      as MCID. For patients with glenohumeral osteoarthritis treated with an aTSA, the 
      MCID values were 12.3 points for WOOS and 4.3 points for OSS. To our knowledge, 
      this is the first study to report a MCID value for WOOS and the first study to 
      report a MCID value for OSS in this subgroup of patients.
CI  - (c) 2021 Nyring et al.
FAU - Nyring, Marc Randall Kristensen
AU  - Nyring MRK
AUID- ORCID: 0000-0002-1511-9309
AD  - Department of Orthopedic Surgery, Herlev and Gentofte Hospital, Hellerup, 2900, 
      Denmark.
FAU - Olsen, Bo Sanderhoff
AU  - Olsen BS
AUID- ORCID: 0000-0002-3509-0742
AD  - Department of Orthopedic Surgery, Herlev and Gentofte Hospital, Hellerup, 2900, 
      Denmark.
FAU - Amundsen, Alexander
AU  - Amundsen A
AUID- ORCID: 0000-0001-9245-9430
AD  - Department of Orthopedic Surgery, Herlev and Gentofte Hospital, Hellerup, 2900, 
      Denmark.
FAU - Rasmussen, Jeppe Vejlgaard
AU  - Rasmussen JV
AUID- ORCID: 0000-0001-5886-1629
AD  - Department of Orthopedic Surgery, Herlev and Gentofte Hospital, Hellerup, 2900, 
      Denmark.
LA  - eng
PT  - Journal Article
DEP - 20210922
PL  - New Zealand
TA  - Patient Relat Outcome Meas
JT  - Patient related outcome measures
JID - 101551170
PMC - PMC8473013
OTO - NOTNLM
OT  - anatomical total shoulder arthroplasty
OT  - glenohumeral osteoarthritis
OT  - minimal clinically important difference
OT  - patient reported outcome measures
COIS- Bo Sanderhoff Olsen, Alexander Amundsen and Jeppe Vejlgaard Rasmussen received 
      institutional support from DePuy Synthes for conducting the study "Functional 
      outcome and complications after Global Unite prostheses" which provided data for 
      the present study. In addition, Bo Sanderhoff Olsen and Jeppe Vejlgaard Rasmussen 
      are paid speakers for DePuy Synthes (Raynham, Massachusetts, United States of 
      America). Jeppe Vejlgaard Rasmussen reports speaker fees from Johnson and Johnson 
      and Zimmer Biomet, outside the submitted work. The authors report no other 
      conflicts of interest in this work.
EDAT- 2021/10/01 06:00
MHDA- 2021/10/01 06:01
PMCR- 2021/09/22
CRDT- 2021/09/30 07:09
PHST- 2021/05/21 00:00 [received]
PHST- 2021/07/15 00:00 [accepted]
PHST- 2021/09/30 07:09 [entrez]
PHST- 2021/10/01 06:00 [pubmed]
PHST- 2021/10/01 06:01 [medline]
PHST- 2021/09/22 00:00 [pmc-release]
AID - 316920 [pii]
AID - 10.2147/PROM.S316920 [doi]
PST - epublish
SO  - Patient Relat Outcome Meas. 2021 Sep 22;12:299-306. doi: 10.2147/PROM.S316920. 
      eCollection 2021.